The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis.
The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNgamma and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.
Sredni-Kenigsbuch
Dvora
D
Shohat
Michael
M
Shohat
Batia
B
Ben-Amitai
Dan
D
Chan
Chi-Chao
CC
David
Michael
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology*; D005030:Ethylenes / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D016753:Interleukin-10 / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D005030:Ethylenes; C508609:IL10 protein, human; D016753:Interleukin-10; C054105:ammonium trichloro(dioxoethylene-O,O'-)tellurate; D048051:p38 Mitogen-Activated Protein Kinases